Literature DB >> 9187108

TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

D M Li1, H Sun.   

Abstract

It has long been postulated that protein tyrosine phosphatases may act as tumor suppressors because of their ability to counteract the oncogenic actions of protein tyrosine kinases. Here we report the cloning and characterization of a novel human protein tyrosine phosphatase, TEP1. TEP1 contains the protein tyrosine phosphatase signature motif, and we show that it possesses an intrinsic protein tyrosine phosphatase activity. TEP1 also shares extensive homology with tensin, a cytoskeletal protein localized to focal adhesions, and with auxilin, a protein involved in synaptic vesicle transport. Immunofluorescence studies show that TEP1 is a cytoplasmic protein. The abundance of TEP1 transcription is altered in many transformed cells. In the transforming growth factor beta-sensitive cells, TEP1 expression is rapidly down-regulated by transforming growth factor beta, a cytokine shown to be involved in regulating cell adhesion and cell motility. We have also mapped the gene encoding TEP1 to chromosome 10q23, a locus that is frequently deleted in a variety of human cancers. TEP1 protein is identical to the protein encoded by the candidate tumor suppressor gene PTEN/MMAC1. Our functional studies of the TEP1 protein suggest that its tumor suppressor function may associate with its intrinsic protein tyrosine phosphatase activity and its cytoplasmic localization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  251 in total

1.  Phosphorylation of the PTEN tail regulates protein stability and function.

Authors:  F Vazquez; S Ramaswamy; N Nakamura; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  A role for nuclear PTEN in neuronal differentiation.

Authors:  M B Lachyankar; N Sultana; C M Schonhoff; P Mitra; W Poluha; S Lambert; P J Quesenberry; N S Litofsky; L D Recht; R Nabi; S J Miller; S Ohta; B G Neel; A H Ross
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

3.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Establishment and characterization of nine human brain tumor cell lines.

Authors:  K H Shin; G Choe; Y J Park; J H Jang; H W Jung; J G Park
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Nov-Dec       Impact factor: 2.416

5.  Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor.

Authors:  J Stolarov; K Chang; A Reiner; L Rodgers; G J Hannon; M H Wigler; V Mittal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

6.  Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Authors:  G B Mills; Y Lu; E C Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 7.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

8.  Hypoxia induces cardiac fibroblast proliferation and phenotypic switch: a role for caveolae and caveolin-1/PTEN mediated pathway.

Authors:  Yao Gao; Ming Chu; Jian Hong; Jingping Shang; Di Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

9.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 10.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.